| Tuesday, Feb. 14, 2023 This map shows the location of Marburg virus disease outbreaks across the world. In an outbreak of Marburg virus disease, NIAID scientists are confident they can greatly extend dose availability of a fully protective, single injection, quick-acting experimental vaccine by using doses much less potent that originally tested. A new study, published in eBioMedicine from NIAID scientists at Rocky Mountain Laboratories, shows that the vaccine (VSV-MARV) provides full protection in cynomolgus macaques at doses up to 10,000 times less potent than originally tested. The vaccine, which is being developed by Public Health Vaccines, uses vesicular stomatitis virus (VSV) to deliver the protective viral protein. This is the same method used to develop Ervebo, the first licensed vaccine against Ebola virus, which is closely related to Marburg. The scientists specifically designed the study to prepare for an emergency outbreak situation and clinical development. Equatorial Guinea this week identified its first outbreak of Marburg virus disease, which has a case fatality rate of up to 88%. The disease also was found in other new parts of Africa the past two years – Guinea in 2021 and Ghana in 2022. African fruit bats are the natural host of Marburg virus.  |
No comments:
Post a Comment